29th Jan 2007 07:01
Vernalis PLC29 January 2007 29 January 2007 Vernalis Plc: Notice of Full Year 2006 Preliminary Results WINNERSH, U.K., January 29, 2007 -- Vernalis plc (LSE: VER, Nasdaq: VNLS) todayannounces that it will be releasing its preliminary results for the twelvemonths ended 31 December 2006 on Monday, 12 March 2007. An analyst briefing will be held at 9.30 a.m. on 12 March at the offices ofPiper Jaffray Ltd, Fifth Floor, One South Place, London EC2M 2RB. -- ends -- Enquiries:Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy Lazar Partners Ltd 212-867-1762Gregory Gin Notes to Editors About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has eight products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit: www.vernalis.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC